Back to All

OncLive interviews Diaceutics at EHA Congress 2019: Retesting for FLT3 Mutation Status in AML

19 July, 2019

A recent study of FLT3 testing behavior in relapsed acute myeloid leukemia (AML) conducted by experts at Diaceutics has uncovered the need for faster laboratory testing turnaround times (TAT). CTO at Diaceutics, Jordan Clark discussed the findings with OncLiveL1 at this year’s EHA Congress where the abstract was accepted for publication. The abstract analyzes the FLT3 testing behavior in relapsed acute myeloid leukemia (AML) over the course of a year. Read the full abstract hereL2

Link References

1. OncLive

2. here

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny